527 related articles for article (PubMed ID: 27855634)
1. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
[TBL] [Abstract][Full Text] [Related]
2. Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury.
Awad AS; You H; Gao T; Gvritishvili A; Cooper TK; Tombran-Tink J
PLoS One; 2015; 10(7):e0133777. PubMed ID: 26207369
[TBL] [Abstract][Full Text] [Related]
3. PEDF relieves kidney injury in type 2 diabetic nephropathy mice by reducing macrophage infiltration.
Li L; Zhang L; Chen D; Yu K; Gan H; Yang G
Endokrynol Pol; 2021; 72(6):643-651. PubMed ID: 34647607
[TBL] [Abstract][Full Text] [Related]
4. Genomic expression profiling and bioinformatics analysis on diabetic nephrology with ginsenoside Rg3.
Wang J; Cui C; Fu L; Xiao Z; Xie N; Liu Y; Yu L; Wang H; Luo B
Mol Med Rep; 2016 Aug; 14(2):1162-72. PubMed ID: 27279428
[TBL] [Abstract][Full Text] [Related]
5. Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.
Awad AS; Gao T; Gvritishvili A; You H; Liu Y; Cooper TK; Reeves WB; Tombran-Tink J
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F891-900. PubMed ID: 23884140
[TBL] [Abstract][Full Text] [Related]
6. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice.
Liu Y; Leo LF; McGregor C; Grivitishvili A; Barnstable CJ; Tombran-Tink J
Mol Med; 2012 Dec; 18(1):1387-401. PubMed ID: 23019073
[TBL] [Abstract][Full Text] [Related]
7. Protective Role of PEDF-Derived Synthetic Peptide Against Experimental Diabetic Nephropathy.
Ishibashi Y; Matsui T; Taira J; Higashimoto Y; Yamagishi S
Horm Metab Res; 2016 Sep; 48(9):613-9. PubMed ID: 27214310
[TBL] [Abstract][Full Text] [Related]
8. Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway.
He X; Cheng R; Park K; Benyajati S; Moiseyev G; Sun C; Olson LE; Yang Y; Eby BK; Lau K; Ma JX
Kidney Int; 2017 Mar; 91(3):642-657. PubMed ID: 27914705
[TBL] [Abstract][Full Text] [Related]
9. An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy.
Xiao Y; Liu Y; Lai Z; Huang J; Li C; Zhang Y; Gong X; Deng J; Ye X; Li X
J Ethnopharmacol; 2021 Apr; 270():113806. PubMed ID: 33444721
[TBL] [Abstract][Full Text] [Related]
10. Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generation sequencing.
Kesherwani V; Shahshahan HR; Mishra PK
PLoS One; 2017; 12(8):e0182828. PubMed ID: 28837672
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy.
Wang JJ; Zhang SX; Mott R; Chen Y; Knapp RR; Cao W; Ma JX
Am J Physiol Renal Physiol; 2008 May; 294(5):F1166-73. PubMed ID: 18322021
[TBL] [Abstract][Full Text] [Related]
12. RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models.
Yang H; Zhang Z; Peng R; Zhang L; Liu H; Wang X; Tian Y; Sun Y
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33779731
[TBL] [Abstract][Full Text] [Related]
13. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the molecular mechanisms and potential therapeutic targets for diabetic nephropathy by bioinformatics methods.
Wang WN; Zhang WL; Zhou GY; Ma FZ; Sun T; Su SS; Xu ZG
Int J Mol Med; 2016 May; 37(5):1181-8. PubMed ID: 26986014
[TBL] [Abstract][Full Text] [Related]
15. Whole transcriptome analysis of diabetic nephropathy in the db/db mouse model of type 2 diabetes.
Wen L; Zhang Z; Peng R; Zhang L; Liu H; Peng H; Sun Y
J Cell Biochem; 2019 Oct; 120(10):17520-17533. PubMed ID: 31106482
[TBL] [Abstract][Full Text] [Related]
16. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.
Delić D; Eisele C; Schmid R; Baum P; Wiech F; Gerl M; Zimdahl H; Pullen SS; Urquhart R
PLoS One; 2016; 11(3):e0150154. PubMed ID: 26930277
[TBL] [Abstract][Full Text] [Related]
17. Whole transcriptome mapping reveals the lncRNA regulatory network of TFP5 treatment in diabetic nephropathy.
Luo H; Yang L; Zhang G; Bao X; Ma D; Li B; Cao L; Cao S; Liu S; Bao L; E J; Zheng Y
Genes Genomics; 2024 May; 46(5):621-635. PubMed ID: 38536617
[TBL] [Abstract][Full Text] [Related]
18. RNA-Seq Analysis of ceRNA-Related Networks in the Regulatory Metabolic Pathway of Mice with Diabetic Nephropathy Subjected to Empagliflozin Intervention.
Wu T; Zhang Z; Huang H; Wu X
Arch Esp Urol; 2023 Nov; 76(9):680-689. PubMed ID: 38053423
[TBL] [Abstract][Full Text] [Related]
19. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.
Rudnicki M; Beckers A; Neuwirt H; Vandesompele J
Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv35-42. PubMed ID: 26209736
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of the gene expression profile of the male and female BTBR mice with diabetic nephropathy.
Xue R; Wang Y; Geng L; Xiao H; Kumar V; Lan X; Malhotra A; Singhal PC; Chen J
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128720. PubMed ID: 38101684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
